{"id":"https://openalex.org/W2907176303","doi":"https://doi.org/10.1182/blood-2018-99-114779","title":"Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)","display_name":"Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2907176303","doi":"https://doi.org/10.1182/blood-2018-99-114779","mag":"2907176303"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-114779","doi":"https://doi.org/10.1182/blood-2018-99-114779","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-114779","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A. Mesa","raw_affiliation_strings":["UT Health San Antonio MD Anderson, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Health San Antonio MD Anderson, San Antonio, TX","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018111458","display_name":"Francisco Cervantes","orcid":"https://orcid.org/0000-0003-2664-8131","observed_orcids":["https://orcid.org/0000-0003-2664-8131"]},"institutions":[{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Francisco Cervantes","raw_affiliation_strings":["Hospital Clinic, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Clinic, Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046827092","display_name":"Claire N. Harrison","orcid":"https://orcid.org/0000-0002-3212-920X","observed_orcids":["https://orcid.org/0000-0002-3212-920X"]},"institutions":[{"id":"https://openalex.org/I200166805","display_name":"Guy's and St Thomas' NHS Foundation Trust","ror":"https://ror.org/00j161312","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200166805"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire N. Harrison","raw_affiliation_strings":["Department of Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I200166805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025797543","display_name":"Adam J. Mead","orcid":"https://orcid.org/0000-0001-8522-1002","observed_orcids":["https://orcid.org/0000-0001-8522-1002"]},"institutions":[{"id":"https://openalex.org/I2801179840","display_name":"Churchill Hospital","ror":"https://ror.org/009vheq40","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801179840","https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Adam J. Mead","raw_affiliation_strings":["NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom","institution_ids":["https://openalex.org/I2801179840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046772202","display_name":"Alessandro Maria Vannucchi","orcid":"https://orcid.org/0000-0001-5755-0730","observed_orcids":["https://orcid.org/0000-0001-5755-0730"]},"institutions":[{"id":"https://openalex.org/I45084792","display_name":"University of Florence","ror":"https://ror.org/04jr1s763","country_code":"IT","type":"education","lineage":["https://openalex.org/I45084792"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessandro M. Vannucchi","raw_affiliation_strings":["AOU Careggi and University of Florence, Florence, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AOU Careggi and University of Florence, Florence, Italy","institution_ids":["https://openalex.org/I45084792"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100442914","display_name":"Lixia Wang","orcid":"https://orcid.org/0000-0002-2304-7536","observed_orcids":["https://orcid.org/0000-0002-2304-7536"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lixia Wang","raw_affiliation_strings":["CTI BioPharma Corp., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CTI BioPharma Corp., Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014292494","display_name":"Tanya Granston","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Tanya Granston","raw_affiliation_strings":["CTI BioPharma Corp., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CTI BioPharma Corp., Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072336042","display_name":"John O Mascarenhas","orcid":"https://orcid.org/0000-0002-8400-0483","observed_orcids":["https://orcid.org/0000-0002-8400-0483"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Mascarenhas","raw_affiliation_strings":["Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5014292494","https://openalex.org/A5100442914"],"corresponding_institution_ids":["https://openalex.org/I4210101701"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"4281","last_page":"4281"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9869999885559082},{"id":"https://openalex.org/keywords/pacritinib","display_name":"pacritinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/total-symptom-score","display_name":"total symptom score","score":0.9409999847412109},{"id":"https://openalex.org/keywords/best-available-therapy","display_name":"best available therapy","score":0.6690000295639038},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.828000009059906},{"id":"https://openalex.org/keywords/symptomatic-response","display_name":"symptom response","score":0.5400000214576721},{"id":"https://openalex.org/keywords/pooled-analysis","display_name":"pooled analysis","score":0.48899999260902405},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.7509999871253967},{"id":"https://openalex.org/keywords/spleen-volume-reduction","display_name":"spleen volume reduction","score":0.75},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.5929999947547913},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.8199999928474426}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.9462069272994995},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8282546997070312},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8108237981796265},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.7566969394683838},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6548942923545837},{"id":"https://openalex.org/C2779788118","wikidata":"https://www.wikidata.org/wiki/Q1542410","display_name":"Thrombocytosis","level":3,"score":0.4901965260505676},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3341912627220154},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3223326802253723},{"id":"https://openalex.org/C89560881","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet","level":2,"score":0.2584458887577057},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.13509920239448547}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-114779","doi":"https://doi.org/10.1182/blood-2018-99-114779","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-114779","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2890676078","https://openalex.org/W2979663993","https://openalex.org/W3215943156","https://openalex.org/W4389231294","https://openalex.org/W4386071127","https://openalex.org/W2415673409","https://openalex.org/W2305182036","https://openalex.org/W4400108946","https://openalex.org/W2553053730","https://openalex.org/W4379282483"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],":":[2,135,367,620],"MF":[3,29,78,154,183,330,414,503,669],"is":[4],"a":[5,114,138,163,409,565],"hematologic":[6],"malignancy":[7],"characterized":[8],"by":[9,607],"splenomegaly":[10],"and":[11,49,57,72,100,111,184,198,227,305,316,353,389,398,405,431,437,469,491,502,518,593,613,629,663],"debilitating":[12],"systemic":[13],"symptoms.":[14],"The":[15,62,621],"Myeloproliferative":[16],"Neoplasm":[17],"Symptom":[18],"Assessment":[19],"Form":[20],"(MPN-SAF)":[21],"questionnaire":[22,217,475,525],"was":[23,127,137,162,256,322,584,652],"developed":[24],"for":[25,54,329,360,403,464,514,519,658],"patient":[26,397],"self-report":[27],"of":[28,39,52,80,117,142,167,191,200,215,261,282,333,412,442,450,473,488,511,523,542,570,611,638,671,727,739,805,816,827,859,881,892],"symptoms":[30,59,310,547],"(Emanuel":[31],"2012).":[32],"Although":[33],"there":[34],"have":[35,43],"been":[36],"several":[37],"versions":[38,214,472,522],"this":[40],"questionnaire,":[41],"they":[42],"demonstrated":[44,67],"consistent":[45],"reliability,":[46],"cross-sectional":[47],"validity,":[48],"high":[50],"level":[51],"comparability":[53],"both":[55,123,248,346],"TSS":[56,108,120,132,221,229,244,255,267,276,295,304,307,334,388,394,423,454,466,477,479,512,516,536,597,639],"individual":[58],"(Dueck":[60],"2017).":[61],"JAK2/FLT3":[63],"inhibitor":[64],"PAC":[65,143,168,283,404,417,436,461,549,562,642,651],"has":[66],"durable":[68],"spleen":[69,661],"volume":[70,662],"reduction":[71,265,452,660],"symptom":[73,664],"control":[74],"in":[75,84,97,109,151,180,193,222,231,266,311,340,345,351,364,415,435,453,546,560,580,596,615,635,666],"patients":[76,152,181,192,201,226,240,262,349,355,371,384,667],"with":[77,153,157,182,254,356,382,408,460,548,603,641,668,678],"irrespective":[79,670],"baseline":[81,185,269,426,456,492,672],"platelet":[82,673],"count":[83,188,674],"2":[85,213],"phase":[86,124,139,164,626,646],"3":[87,125,140,165,627,647],"trials":[88,126,631],"vs":[89,147,176,284,420,462,500,506,530,643],"BAT":[90,148,177,204,285,406,438,463,582,657],"(Mesa":[91],"2017,":[92],"Mascarenhas":[93],"2018).":[94],"Since":[95],"changes":[96],"study":[98,141,166],"design":[99],"external":[101],"factors":[102,328],"limited":[103],"the":[104,209,216,223,232,242,250,259,279,292,301,341,386,392,416,443,470,474,520,524,540,561,581,625,636,659],"ability":[105],"to":[106,129,203,270,457],"assess":[107],"PERSIST-1":[110,136,315,352,628],"PERSIST-2,":[112,237],"respectively,":[113],"pooled":[115,293,302,444,471,521],"analysis":[116,321,445],"all":[118,238,348,354],"available":[119],"data":[121,287,363,543,648],"from":[122,268,314,369,455,624],"undertaken":[128],"further":[130],"evaluate":[131],"response.":[133,335],"Methods":[134],"400":[144,169],"mg":[145,170,174],"QD":[146,171],"(excluding":[149,155],"ruxolitinib)":[150,179],"those":[156],"prior":[158,196,676],"ruxolitinib":[159,197,206],"treatment);":[160],"PERSIST-2":[161,194,630],"or":[172,478,675,729,741,807,818,829,861,883,894],"200":[173],"BID":[175],"(including":[178],"thrombocytopenia":[186],"(platelet":[187],"\u2264100x109/L);":[189],"48%":[190],"had":[195],"44%":[199],"randomized":[202,350],"received":[205],"treatment":[207,489,497,677],"during":[208],"study.":[210],"In":[211,236,247,278,483],"PERSIST-1,":[212],"were":[218,288,338,380,401,427,508,550,601],"administered;":[219],"MPN-SAF":[220,228,243,275,294,303,306,387,393,465,515],"first":[224],"179":[225,378,383],"2.0":[230,245,296,308,467,517],"subsequent":[233],"148":[234],"patients.":[235],"311":[239],"used":[241],"questionnaire.":[246],"trials,":[249],"efficacy":[251,343],"endpoint":[252],"associated":[253],"defined":[257],"as":[258,298,300,331,553,555,605],"proportion":[260],"achieving":[263],"\u226550%":[264,451],"Week":[271,361,458,556,573,587,599],"24":[272,362,459,600],"based":[273,290],"on":[274,291,723,735,801,812,823,855,877,888],"2.0.":[277,395],"post-hoc":[280],"analyses":[281,337,487],"herein,":[286],"presented":[289],"responses,":[297],"well":[299],"(6":[309],"common)":[312],"responses":[313],"PERSIST-2.":[317,365],"A":[318],"multivariate":[319,484],"stepwise":[320],"also":[323],"performed":[324,339],"using":[325],"potential":[326,493],"prognostic":[327,494],"predictors":[332,510],"These":[336],"intent-to-treat":[342],"populations":[344],"studies:":[347],"randomization":[357],"date":[358],"allowing":[359],"Results":[366,441],"Data":[368],"548":[370],"(n":[372],"=":[373,377],"369":[374,390],"PAC,":[375],"n":[376],"BAT)":[379,501],"analyzed,":[381],"administered":[385,391],"Baseline":[396],"disease":[399],"characteristics":[400],"balanced":[402],"groups,":[407,439],"higher":[410,448],"rate":[411,569,579,637],"primary":[413],"group":[418,490,498,563,583],"(66%":[419],"57%).":[421],"Median":[422],"scores":[424],"at":[425,598],"19.5":[428],"(range,":[429,433],"0.3-57.3)":[430],"19.6":[432],"1.6-55.9)":[434],"respectively.":[440],"demonstrate":[446,632,649],"significantly":[447,534,653],"rates":[449],"(P=0.0241)":[468],"(MPN-SAF":[476],"2.0;":[480],"P<0.0001;":[481],"Table).":[482],"logistic":[485],"regression":[486],"variables,":[495],"only":[496],"(PAC":[499],"type":[504],"(secondary":[505],"primary)":[507],"significant":[509,633],"response":[513,537,568,578,640],"(Table":[526,617],"1).":[527],"Study":[528],"(PERSIST-1":[529],"PERSIST-2)":[531],"did":[532],"not":[533],"impact":[535],"(P=0.2243),":[538],"supporting":[539],"validity":[541],"pooling.":[544],"Reduction":[545],"rapid,":[551],"occurring":[552],"early":[554],"4":[557],"(Figure).":[558],"Patients":[559],"achieved":[564],"steady":[566,576],"state":[567,577],"\u224835%":[571],"around":[572,586],"20,":[574],"while":[575],"\u224815%":[585],"12.":[588],"Additionally,":[589],"larger":[590],"absolute":[591],"reductions":[592,595],"percent":[594],"correlated":[602],"improvement":[604,634],"measured":[606],"Patient":[608],"Global":[609],"Impression":[610],"Change":[612],"change":[614],"EQ-5D-5L":[616],"2).":[618],"Conclusions":[619],"integrated":[622],"results":[623],"BAT.":[644],"Overall,":[645],"that":[650],"more":[654],"effective":[655],"than":[656],"burden":[665],"JAK2":[679],"inhibitors.":[680],"Disclosures":[681],"Mesa:":[682],"Pfizer:":[683],"Research":[684,690,693,696,700,703,716,719,753,777,785,788,793,832,847,850,864,867,870,873,897],"Funding;":[685,691,694,697,701,704,717,778,786,789,848,851,865,868,871,874],"Novartis:":[686,732,790,821,849],"Consultancy;":[687,775,780,783,798],"Incyte":[688],"Corporation:":[689],"Promedior:":[692,869],"Gilead:":[695,769],"NS":[698],"Pharma:":[699],"Celgene:":[702,760,776,799,875],"UT":[705],"Health":[706],"San":[707],"Antonio":[708],"-":[709],"Mays":[710],"Cancer":[711],"Center:":[712],"Employment;":[713],"CTI":[714,765,852],"Biopharma:":[715,853],"Genentech:":[718],"Funding.":[720,898],"Cervantes:Celgene:":[721],"Membership":[722,734,800,811,822,854,876,887],"an":[724,736,802,813,824,856,878,889],"entity's":[725,737,803,814,825,857,879,890],"Board":[726,738,804,815,826,858,880,891],"Directors":[728,740,806,817,828,860,882,893],"advisory":[730,742,808,819,830,862,884,895],"committees;":[731,809,820,885],"Honoraria,":[733,752,762,770,792],"committees,":[743,831,863,896],"Speakers":[744,755,763,771,795,834],"Bureau;":[745,756,764],"Hospital":[746],"Clinic":[747],"Barcelona:":[748],"Employment.":[749],"Harrison:Novartis:":[750],"Consultancy,":[751,758,761,767,791],"Funding,":[754,794,833],"Roche:":[757,866],"Honoraria;":[759,768],"BioPharma:":[766,837,842],"Bureau.":[772,796,835],"Mead:Bristol-Myers":[773],"Squibb:":[774],"ARIAD:":[779],"Cell":[781],"Therapeutics:":[782],"Elstar:":[784],"Evotek:":[787],"Verstovsek:Incyte:":[797],"Italfarmaco:":[810],"Wang:CTI":[836],"Employment,":[838,843],"Equity":[839,844],"Ownership.":[840,845],"Granston:CTI":[841],"Mascarenhas:Merck:":[846],"Janssen:":[872],"Incyte:":[886]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-01-11T00:00:00"}